Renaissance Technologies’s Vor Biopharma VOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.3M Buy
+128,839
New +$1.82M ﹤0.01% 1830
2025
Q4
Sell
-14,600
Closed -$711K 3796
2025
Q3
$711K Sell
14,600
-8,806
-38% -$354K ﹤0.01% 2650
2025
Q2
$758K Sell
23,406
-11,666
-33% -$103K ﹤0.01% 2636
2025
Q1
$503K Buy
35,072
+8,597
+32% +$206K ﹤0.01% 2740
2024
Q4
$588K Sell
26,475
-11,326
-30% -$188K ﹤0.01% 2770
2024
Q3
$529K Buy
37,801
+13,036
+53% +$238K ﹤0.01% 2767
2024
Q2
$495K Buy
24,765
+8,032
+48% +$260K ﹤0.01% 2694
2024
Q1
$793K Buy
16,733
+14,153
+549% +$621K ﹤0.01% 2631
2023
Q4
$116K Buy
2,580
+755
+41% +$31.2K ﹤0.01% 3266
2023
Q3
$77K Buy
1,825
+5
+0.3% +$271 ﹤0.01% 3300
2023
Q2
$112K Buy
1,820
+400
+28% +$36.5K ﹤0.01% 3444
2023
Q1
$153K Sell
1,420
-878
-38% -$97.3K ﹤0.01% 3366
2022
Q4
$306K Buy
2,298
+703
+44% +$69.6K ﹤0.01% 3210
2022
Q3
$127K Buy
1,595
+730
+84% +$71.8K ﹤0.01% 3517
2022
Q2
$86K Buy
+865
New +$88.5K ﹤0.01% 3886

Other funds holding VOR

Renaissance Technologies's VOR Position: Q1 2026 in Review

Renaissance Technologies opened a new position in Vor Biopharma (VOR) in Q1 2026: 128,839 shares worth $2.3M. The stake represents ﹤0.01% of the portfolio and ranks #1830 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in VOR as recently as Q3 2025.

Renaissance Technologies first reported a position in VOR in Q2 2022 and has held it in 15 quarters since. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Renaissance Technologies held 128,839 shares of Vor Biopharma worth $2.3M as of Q1 2026.
  • Vor Biopharma was a new Renaissance Technologies position in Q1 2026.
  • Vor Biopharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1830 holding.
  • Renaissance Technologies first reported a position in Vor Biopharma in Q2 2022 and has held it in 15 quarters since.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.